• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.56% Nasdaq Down0.79%

    More On IPN.PA



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Ipsen S.A. (IPN.PA)

    52.06 Down 0.21(0.40%) 3:22AM EDT
    ProfileGet Profile for:
    Ipsen S.A.
    65, quai Georges Gorse
    Boulogne-Billancourt, 92650
    France - Map
    Phone: 33 1 58 33 50 00
    Fax: 33 1 58 33 50 01
    Website: http://www.ipsen.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:4,304

    Business Summary 

    Ipsen S.A. operates as a pharmaceutical company worldwide. It operates through two segments, Primary Care and Specialty Care. The company offers drugs in uro-oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and cardiovascular areas. Its products include Decapeptyl, a peptide formulation for injection for the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline, which is used primarily in the treatment of acromegaly and neuroendocrine tumors. The company also provides NutropinAq, a liquid formulation for use in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it offers Smecta, a natural clay-based drug for use in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan, an oral formulation, which is used for the treatment of age-related cognitive disorders. Further, the company provides Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl products. Ipsen S.A. has a research collaboration with Interprotein Corporation; and a collaborative agreement with Dassault Systmes SA. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Ipsen S.A.

    Key Executives 
    Mr. Marc M.P. de Garidel , 58
    Chairman, Chief Exec. Officer and Chairman of Strategic Committee
    Mr. Aymeric Le Chatelier , 47
    Exec. VP of Fin. and Member of Chairman's Committee
    Mr. Pierre Kemula ,
    VP of Corp. Fin., Treasury and Financial Markets
    Dr. Claude Bertrand , 54
    Chief Scientific Officer and Exec. VP of R&D
    Mr. Stéphane Durant des Aulnois ,
    Vice-Pres of Investor Relations
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.